Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;22(8):e358-e368.
doi: 10.1016/S1470-2045(21)00343-0.

Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer

Affiliations
Review

Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer

Nan Zhang et al. Lancet Oncol. 2021 Aug.

Abstract

Epithelial-mesenchymal transition (EMT) is a process during which cells lose their epithelial characteristics, for instance apical-basal cell polarity and cell-cell contact, and gain mesenchymal properties, such as increased motility. In colorectal cancer, EMT has an important role in tumour progression, metastasis, and drug resistance. There has been accumulating evidence from preclinical and early clinical studies that show that EMT markers might serve as outcome predictors and potential therapeutic targets in colorectal cancer. This Review describes the fundamentals of EMT, including biology, newly partial EMT, and associated changes. We also provide a comprehensive summary of therapeutic compounds capable of targeting EMT markers, including drugs in preclinical and clinical trials and those with repurpose potential. Lastly, we explore the obstacles of EMT bench-to-bedside drug development.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests DK reports grants from University of Oxford-Sichuan University Huaxi Joint Centre for Gastrointestinal Cancer; consultation fees from SAB and Indivumed; and stock options as director from Oxford Cancer Biomarkers and Celleron Therapeutics. All other authors declare no competing interests.

Publication types

MeSH terms

Substances

LinkOut - more resources